Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Gross Margin: 2019-2024

Historic Gross Margin for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to 72.70%.

  • Silence Therapeutics' Gross Margin rose 20267.00% to 59.75% in Q3 2025 from the same period last year, while for Sep 2025 it was 91.32%, marking a year-over-year increase of 6136.00%. This contributed to the annual value of 72.70% for FY2024, which is 1336.00% up from last year.
  • According to the latest figures from FY2024, Silence Therapeutics' Gross Margin is 72.70%, which was up 22.52% from 59.34% recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Gross Margin ranged from a high of 72.70% in FY2024 and a low of 31.34% during FY2020.
  • Over the past 3 years, Silence Therapeutics' median Gross Margin value was 59.34% (recorded in 2023), while the average stood at 56.62%.
  • Per our database at Business Quant, Silence Therapeutics' Gross Margin crashed by 6,866bps in 2020 and then skyrocketed by 2,151bps in 2023.
  • Silence Therapeutics' Gross Margin (MRY) stood at 31.34% in 2020, then increased by 27bps to 39.94% in 2021, then fell by 5bps to 37.83% in 2022, then skyrocketed by 57bps to 59.34% in 2023, then grew by 23bps to 72.70% in 2024.
  • Its Gross Margin stands at 72.70% for FY2024, versus 59.34% for FY2023 and 37.83% for FY2022.